시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 트랜스티레틴 아밀로이드증 치료 시장 보고서(2025년)
Transthyretin Amyloidosis Treatment Global Market Report 2025
상품코드 : 1825568
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 250 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,430,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,294,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,159,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

트랜스티레틴 아밀로이드증 치료 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에 CAGR은 8.3%를 나타낼 것으로 예측되고 68억 3,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 치료제 파이프라인 확대, 유전자 검사 증가, 희귀질환 인식 제고를 위한 전 세계 노력, 맞춤형 의약품 접근법, 치료 접근성 개선 등에 기인할 수 있습니다. 예측 기간의 주요 동향으로는 복합 요법의 등장, 신약 개발을 위한 전략적 파트너십, 말초 및 심장 증상에 주력, 환자 교육 프로그램 시행, 치료 지침에 실세계 증거(RWE) 반영 등이 있습니다.

향후 5년간 8.3% 성장 전망은 이전 예측 대비 0.2% 소폭 하향 조정된 수치입니다. 이 같은 하향 조정은 주로 미국과 타국 간 관세 영향에 기인합니다. 관세 장벽은 아일랜드와 이탈리아에서 제조되는 유전자 침묵 RNAi 치료제(파티시란/이노터센)의 가격을 상승시켜 미국 내 전문 치료를 저해할 것으로 예상됩니다. 이로 인해 질환 수정 치료 접근성이 제한되고 아밀로이드증 클리닉 예산이 증가할 것입니다. 또한 상호 관세 부과와 무역 긴장 및 제한 강화로 인한 전 세계 경제 및 무역에 대한 부정적 영향으로 그 영향이 더욱 광범위하게 나타날 것입니다.

연구개발(R&D) 투자 증가는 트랜스티레틴 아밀로이드증 치료 시장 성장의 주요 촉진력이 될 것으로 전망됩니다. R&D 투자는 과학적 지식 발전, 신기술 개발, 혁신적 제품 창출, 기존 공정을 향상시키는 데 배정된 재정 자원을 포괄합니다. R&D 사업에 대한 자금 증대는 트랜스티레틴 아밀로이드증에 대한 새로운 치료 방법론의 발견과 발전을 촉진합니다. 이러한 접근법에는 선구적인 의약품, 유전자 치료, 정밀 의학 기술이 포함되며, 이는 환자에게 보다 효과적이고 표적화된 치료 옵션을 제공합니다. 예를 들어 미국에 본사를 둔 바이오 제약 회사인 Alnylam Pharmaceuticals는 R&D 투자를 2021년 79만 2,156달러에서 2022년에 88만 3,015달러로 늘려 11.49%의 성장세를 보였습니다. 따라서 R&D 투자 증가는 트랜스티레틴 아밀로이드증 치료 시장의 성장을 가속할 것으로 예측됩니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Transthyretin amyloidosis is a gradually progressing condition marked by the accumulation of abnormal protein deposits in the body's organs and tissues. Treatment for transthyretin amyloidosis involves various medical interventions and therapeutic strategies aimed at managing and alleviating the impacts of this condition.

The primary categories of transthyretin amyloidosis treatment include transthyretin amyloidosis with polyneuropathy (ATTR-PN) and transthyretin amyloidosis with cardiomyopathy (ATTR-CM). ATTR-PN involves the abnormal deposition of transthyretin protein in nerves, resulting in peripheral neuropathy and other neurological symptoms. Treatment options for these conditions include drugs such as tafamidis, patisiran, inotersen, as well as targeted therapy, supportive therapy, and pipeline therapies. These treatments are made available through various distribution channels, including hospital pharmacies, specialty pharmacies, retail pharmacies, and online pharmacies.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The transthyretin amyloidosis treatment market research report is one of a series of new reports from The Business Research Company that provides transthyretin amyloidosis treatment market statistics, including transthyretin amyloidosis treatment industry global market size, regional shares, competitors with a transthyretin amyloidosis treatment market share, detailed transthyretin amyloidosis treatment market segments, market trends and opportunities, and any further data you may need to thrive in the transthyretin amyloidosis treatment industry. This transthyretin amyloidosis treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future- scenario of the industry.

The transthyretin amyloidosis treatment market size has grown strongly in recent years. It will grow from $4.59 billion in 2024 to $4.96 billion in 2025 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to increased disease awareness, advancements in diagnostic tools, drug development and approvals, patient advocacy and support, collaboration in research.

The transthyretin amyloidosis treatment market size is expected to see strong growth in the next few years. It will grow to $6.83 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to expanded therapeutic pipeline, increased genetic screening, global efforts for rare disease awareness, personalized medicine approaches, improved access to treatment. Major trends in the forecast period include emergence of combination therapies, strategic partnerships for drug development, focus on targeting peripheral and cardiac manifestations, implementation of patient education programs, incorporation of real-world evidence in treatment guidelines.

The forecast of 8.3% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper U.S. specialty care by increasing the price of gene-silencing RNAi therapeutics (patisiran/inotersen) manufactured in Ireland and Italy, thereby limiting access to disease-modifying treatments and elevating amyloidosis clinic budgets. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

Increased investments in research and development (R&D) are projected to be the driving force behind the growth of the transthyretin amyloidosis treatment market. R&D investments encompass financial resources allocated towards advancing scientific knowledge, developing new technologies, creating innovative products, and enhancing existing processes. Augmented funding in R&D endeavors facilitates the discovery and advancement of novel treatment methodologies for transthyretin amyloidosis. These approaches include pioneering drugs, gene therapies, and precision medicine techniques, which offer patients more effective and targeted treatment options. For instance, Alnylam Pharmaceuticals, a US-based biopharmaceutical company, elevated its research and development investment from $792,156 in 2021 to $883,015 in 2022, indicating an 11.49% growth. Thus, the escalating investment in research and development is anticipated to propel the growth of the transthyretin amyloidosis treatment market.

The expanding demographic of the aging population is poised to be a significant driver of growth in the transthyretin amyloidosis treatment market. An aging population signifies a demographic shift characterized by an increased median age due to declining fertility rates and longer life expectancies. Age is a substantial risk factor for transthyretin amyloidosis (ATTR), and as the population ages, the prevalence of cases pertaining to this condition rises. Consequently, there is a growing pool of patients necessitating treatment. For example, according to the World Health Organization's October 2022 report, every country globally is witnessing an upsurge in both the quantity and proportion of older individuals in the population. By 2030, it's projected that 1 in 6 people worldwide will be aged 60 years or older. Hence, the burgeoning demographics of the aging population are steering the growth of the transthyretin amyloidosis treatment market.

Leading companies within the transthyretin amyloidosis treatment sector are prioritizing the development of innovative and specialized therapies, notably orphan drugs, aiming to improve patient outcomes and broaden treatment options. Orphan drugs such as Eplontersen are specifically tailored to address transthyretin amyloidosis, often receiving regulatory advantages to facilitate their development. For instance, Ionis Pharmaceuticals, Inc., a Canada-based biotechnology research company, obtained Food and Drug Administration (FDA) approval for a new drug application concerning Eplontersen in March 2023. Eplontersen, an experimental orphan drug, is intended for the treatment of familial transthyretin-mediated amyloid, which leads to progressive polyneuropathy. Functioning as a pharmaceutical agent, Eplontersen is designed to decrease transthyretin (TTR) protein synthesis, targeting both hereditary and non-hereditary variations of ATTR amyloidosis (amyloid transthyretin amyloidosis). The FDA had granted Eplontersen orphan drug designation in 2022.

In April 2024, BridgeBio Pharma, a US-based biotechnology firm, entered into a collaboration with Bayer to address transthyretin amyloid cardiomyopathy (ATTR-CM) in Europe. As part of the agreement, Bayer will have exclusive rights to commercialize the drug, while BridgeBio will receive up to $310 million in payments and royalties. This partnership increases the likelihood of acoramidis becoming available for patients affected by this serious condition. Bayer is a Germany-based life science company.

Major companies operating in the transthyretin amyloidosis treatment market report are Pfizer Inc., Abbvie Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca PLC, GSK PLC, Novo Nordisk A/S, Merck & Co. Inc., Astellas Pharma Inc., Alexion Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., PTC Therapeutics, Ionis Pharmaceuticals, Prothena Corporation PLC, BridgeBio Pharma Inc., Sorrento Therapeutics Inc., Intellia Therapeutics, Akcea Therapeutics Inc., Eidos Therapeutics Inc., Acrotech Biopharma Inc., Spectrum Pharmaceuticals Inc., Neurimmune AG, BELLUS Health Inc., Corino Therapeutics Inc., Celgene Corp, SOM Innovation Biotech S.A

North America was the largest region in the transthyretin amyloidosis treatment market in 2024. The regions covered in the transthyretin amyloidosis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the transthyretin amyloidosis treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain

The transthyretin amyloidosis treatment market consists of revenues earned by entities by providing biopsy, echocardiography, genetic testing, and imaging studies. The market value includes the value of related goods sold by the service provider or included within the service offering. The transthyretin amyloidosis treatment market also includes sales of tolcapone, and diflunisal. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Transthyretin Amyloidosis Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on transthyretin amyloidosis treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for transthyretin amyloidosis treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The transthyretin amyloidosis treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Scope

Table of Contents

1. Executive Summary

2. Transthyretin Amyloidosis Treatment Market Characteristics

3. Transthyretin Amyloidosis Treatment Market Trends And Strategies

4. Transthyretin Amyloidosis Treatment Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Transthyretin Amyloidosis Treatment Growth Analysis And Strategic Analysis Framework

6. Transthyretin Amyloidosis Treatment Market Segmentation

7. Transthyretin Amyloidosis Treatment Market Regional And Country Analysis

8. Asia-Pacific Transthyretin Amyloidosis Treatment Market

9. China Transthyretin Amyloidosis Treatment Market

10. India Transthyretin Amyloidosis Treatment Market

11. Japan Transthyretin Amyloidosis Treatment Market

12. Australia Transthyretin Amyloidosis Treatment Market

13. Indonesia Transthyretin Amyloidosis Treatment Market

14. South Korea Transthyretin Amyloidosis Treatment Market

15. Western Europe Transthyretin Amyloidosis Treatment Market

16. UK Transthyretin Amyloidosis Treatment Market

17. Germany Transthyretin Amyloidosis Treatment Market

18. France Transthyretin Amyloidosis Treatment Market

19. Italy Transthyretin Amyloidosis Treatment Market

20. Spain Transthyretin Amyloidosis Treatment Market

21. Eastern Europe Transthyretin Amyloidosis Treatment Market

22. Russia Transthyretin Amyloidosis Treatment Market

23. North America Transthyretin Amyloidosis Treatment Market

24. USA Transthyretin Amyloidosis Treatment Market

25. Canada Transthyretin Amyloidosis Treatment Market

26. South America Transthyretin Amyloidosis Treatment Market

27. Brazil Transthyretin Amyloidosis Treatment Market

28. Middle East Transthyretin Amyloidosis Treatment Market

29. Africa Transthyretin Amyloidosis Treatment Market

30. Transthyretin Amyloidosis Treatment Market Competitive Landscape And Company Profiles

31. Transthyretin Amyloidosis Treatment Market Other Major And Innovative Companies

32. Global Transthyretin Amyloidosis Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Transthyretin Amyloidosis Treatment Market

34. Recent Developments In The Transthyretin Amyloidosis Treatment Market

35. Transthyretin Amyloidosis Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기